Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-9

  Laitinen, Iina ^a   Notni, Johannes ^b   Pohle, Karolin ^a   Rudelius, Martina ^b   Farrell, Eliane ^a   Nekolla, Stephan G ^a   Henriksen, Gjermund ^a   Neubauer, Stefanie ^b   Kessler, Horst ^b,c   Wester, Hans Jürgen ^b   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Myocardial infarction; PET

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID GALACTO F 18; ARGINYLGLYCYLASPARTIC ACID NODAGA GA 68; ARGINYLGLYCYLASPARTIC ACID TRAP GA 68; BETA3 INTEGRIN; CD31 ANTIGEN; FLUORINE 18; GALLIUM 68; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG DISTRIBUTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEART INFARCTION; HISTOLOGY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT;

EID: 84878806122     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-38     Document Type: Article

References (38)

1. Liehn EA, Postea O, Curaj A, Marx N: Repair after myocardial infarction, between fantasy and reality: the role of chemokines. J Am Coll Cardiol 2011, 58:2357-2362.
2. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
3. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35:569-582.
4. Sun M, Opavsky MA, Stewart DJ, Rabinovitch M, Dawood F, Wen WH: Temporal response and localization of integrins beta1 and beta3 in the heart after myocardial infarction: regulation by cytokines. Circulation 2003, 107:1046-1052.
5. Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, Su H, Edwards DS, Liu S, Harris TD, Madri JA, Zaret BL, Sinusas AJ: Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 2004, 113:1684-1691.
6. Higuchi T, Bengel FM, Seidl S, Watzlowik P, Kessler H, Hegenloh R, Reder S, Nekolla SG, Wester HJ, Schwaiger M: Assessment of αvβ3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res 2008, 78:395-403.
7. 2. Eur J Nucl Med Mol Imaging 2012, 39:683-692.
8. Sherif HM, Saraste A, Nekolla SG, Weidl E, Reder S, Tapfer A, Rudelius M, Higuchi T, Botnar RM, Wester HJ, Schwaiger M: Molecular imaging of early αvβ3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats. J Nucl Med 2012, 53:318-323.
9. Notni J, Šimeček J, Hermann P, Wester HJ: TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. Chem Eur J 2011, 17:14718-1422.
10. 18F-galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol 2012, 39:777-784.
11. Notni J, Pohle K, Wester HJ: Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET. EJNMMI Res 2012, 2:28.
12. 3. Nucl Med Biol 2013, 40:33-40.
13. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M: Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001, 61:1781-1785.
14. Mas-Moruno C, Rechenmacher F, Kessler H: Cilengitide: the first antiangiogenic small molecule drug candidate. Design, synthesis and clinical evaluation. Anticancer Agents Med Chem 2010, 10:753-768.
15. Dechantsreiter MA, Planker E, Mathä B, Lohof E, Hölzemann G, Jonczyk A, Goodman SL, Kessler H: N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists. J Med Chem 1999, 42:3033-3040.
16. Ross RS: The extracellular connections: the role of integrins in myocardial remodeling. J Card Fail 2002, 8(Suppl 6):326-331.
17. Ross RS, Pham C, Shai SY, Goldhaber JI, Fenczik C, Glembotski CC, Ginsberg MH, Loftus JC: Beta1 integrins participate in the hypertrophic response of rat ventricular myocytes. Circ Res 1998, 82:1160-1172.
18. Johnston RK, Balasubramanian S, Kasiganesan H, Baicu CF, Zile MR, Kuppuswamy D: Beta3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. FASEB J 2009, 23:2759-2771.
19. Cheng Z, DiMichele LA, Hakim ZS, Rojas M, Mack CP, Taylor JM: Targeted focal adhesion kinase activation in cardiomyocytes protects the heart from ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 2012, 32:924-933.
20. Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer A: Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging 2012, 39(Suppl 1):126-138.
21. Schottelius M, Laufer B, Kessler H, Wester HJ: Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res 2009, 42:969-980.
22. Pfaff M, Tangemann K, Müller B, Gurrath M, Müller G, Kessler H, Timpl R, Engel J: Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol Chem 1994, 269:20233-20238.
23. Weide T, Modlinger A, Kessler H: Spatial screening for the identification of the bioactive conformation of integrin ligands. Top Curr Chem 2007, 272:1-50.
24. 3 expression. Theranostics 2011, 1:48-57.
25. 99mTc-RAFT-RGD. J Nucl Cardiol 2010, 17:435-443.
26. 68Ga tracers for positron emission tomography. Chem Eur J 2010, 16:7174-7185.
27. Šimeček J, Schulz M, Notni J, Plutnar J, Kubíček V, Havlíčková J, Hermann P: Complexation of metal ions with TRAP (1,4,7-triazacyclononane phosphinic acid) ligands and NOTA: phosphinate-containing ligands as unique chelators for trivalent gallium. Inorg Chem 2012, 51:577-590.
28. Thumshirn G, Hersel U, Goodman SL, Kessler H: Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chem Eur J 2003, 9:2717-2725.
29. 3 expression. Eur J Nucl Med Mol Imaging 2008, 35:1100-1108.
30. Shi J, Zhou Y, Chakraborty S, Kim YS, Jia B, Wang F, Liu S: Evaluation of in-labeled cyclic RGD peptides: effects of peptide and linker multiplicity on their tumor uptake, excretion kinetics and metabolic stability. Theranostics 2011, 1:322-340.
31. Nawata J, Ohno I, Isoyama S, Suzuki J, Miura S, Ikeda J, Shirato K: Differential expression of alpha 1, alpha 3 and alpha 5 integrin subunits in acute and chronic stages of myocardial infarction in rats. Cardiovasc Res 1999, 43:371-381.
32. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stöcklin G, Schwaiger M: Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999, 40:1061-1071.
33. Hynes R: Integrins: bidirectional, allosteric signalling machines. Cell 2002, 110:673-687.
34. Brooks PC, Clark RA, Cheresh DA: Requirements of vascular integrin avß3 for angiogenesis. Science 1994, 264:569-571.
35. Clark RA, Tonnesen MG, Gailit J, Cheresh DA: Transient functional expression of avß3 on vascular cells during wound repair. Am J Pathol 1996, 148:1407-1421.
36. van den Borne SW, Isobe S, Verjans JW, Petrov A, Lovhaug D, Li P, Zandbergen HR, Ni Y, Frederik P, Zhou J, Arbo B, Rogstad A, Cuthbertson A, Chettibi S, Reutelingsperger C, Blankesteijn WM, Smits JF, Daemen MJ, Zannad F, Vannan MA, Narula N, Pitt B, Hofstra L, Narula J: Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol 2008, 52:2017-2028.
37. Savill J, Dransfield I, Hogg N, Haslett C: Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990, 343:170-173.
38. 5-integrin imaging agent. J Nucl Med 2011, 52:424-430.